Articles By Jack Cush, MD
NIH Study Shows 11.2% of Americans in Pain
Using statistics gathered by the NIH in 2012, the National Health Interview Survey of 8781 adults showed self-reported chronic pain affects 25.3 million adults, or 11.2% of the populatoin.
Read Article
Rituximab Induced Neutropenia
In reviewing submitted abstracts for the 2014 ACR meeting, I was surprised by several abstracts focusing on neutropenia in patients receiving rituximab.
Read Article
Electronic Health Records Gets Low Scores Among Physicians
A recent survey by AmericanEHR Partners and the AMA of 940 physicians, physician assistants and nurse practitioners showed most physicians are dissatisfied with their EHR systems.
Read Article
Testosterone Therapy Yields No Cardiovascular Harm
Are the benefits of androgen supplementation in older men overstated? Might the risks be understated?
Read Article
Metformin May Improve Netosis Driven Lupus Activity
Neutrophil extracellular traps (NETs) are first line defense tools used to trap microbial pathogens.
Read Article
Statins Improve CV risk in RA
Since publication of the Jupiter trial that showed statin effects may include the lowering of C-reactive protein levels and inflammation, there have been several efforts to study the adjunctive effects of statins in rheumatoid arthritis treatment.
Read Article
International Psoriasis Council Publishes its Research Priorities
The British Journal of Dermatology has published online the results of an International Psoriasis Council (IPC) survey identifying 21 psoriasis research priorities. The results will also appear in a future print edition of the journal.
Read ArticleMinority of Nonradiographic-Axial SpA Patients will Progress to Ankylosing Spondylitis
Wang and coworkers from the Rochester Epidemiology Project presented their findings at the annual Spondyloarthritis Research and Treatment Network.(SPARTAN) in Denver, CO.
Read Article
Heel Pain, Uveitis, TB, Vitamin D, Hidradenitis: July 2015 top social media news
In July 2015, RheumNow published 73 tweets about impactful news, research and teaching points that I feel will have an impact on the rheumatology community. We had a reach (impressions) of 49,900, 63 mentions, and 1277 visits to RheumNow.com to check out what we publish.
Read Article
AstraZeneca Pushes Forward on Brodalumab Development
Despite Amgen's withdrawal as a co-developer of brodalumab, the anti-IL17A monoclonal antibody, AstraZeneca has announced it will push its plan to develop the drug. Brodalumab is currently in phase III trials for use in psoriasis, psoriatic arthritis and ankylosing spondylitis.
Read Article
